Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE trial of first-trimester progesterone for unexplained recurrent miscarriage
NL-OMON33690Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in recurrent miscarriage (RPL) comparing Utrogestan with Placebo (2 arms). Primary endpoint: Live birth beyond 24 weeks. Started Aug 2010; status: active, not recruiting.
02
Drugs
progesterone
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on NL-OMON33690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33690.